Results 11 to 20 of about 266,823 (339)

Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease

Scientific Reports, 2021
We evaluated changes in the complement system resulting from anti-vascular endothelial growth factor (VEGF) in eyes with age-related choroidal neovascularization (CNV) including neovascular age-related macular degeneration, pachychoroid neovasculopathy ...
Keiichiro Tanaka, Yasuharu Oguchi, Tomoko Omori, Yumi Ishida, Hiroaki Shintake, Ryutaro Tomita, Akihito Kasai, Masashi Ogasawara, Yukinori Sugano, Kanako Itagaki, Akira Ojima, Takeshi Machida, Hideharu Sekine, Tetsuju Sekiryu   +13 more
doaj   +1 more source

Anti VEGF for post op CME- Boon or Bane!

TNOA Journal of Ophthalmic Science and Research, 2022
Cataract surgery has advanced in techniques and instrumentation over the years, but complications such as cystoid macular edema (CME) do occur even after uneventful surgery.
Roshni Mohan, M Arthi, S Balamurugan
doaj   +1 more source

Intravitreally injected anti-VEGF antibody reduces brown fat in neonatal mice [PDF]

, 2015
Anti-vascular endothelial growth factor (VEGF) agents are the mainstay treatment for various angiogenesis-related retinal diseases. Currently, bevacizumab, a recombinant humanized anti-VEGF antibody, is trailed in retinopathy of prematurity, a ...
A Hellstrom, AL Hard, AM Cypess, B Cannon, BJ Lee, Chang Sik Cho, D Lepore, DF Martin, DH Jo, Dong Hyun Jo, H Kim, HA Mintz-Hittner, HA Mintz-Hittner, HK Sung, I Elias, I Shimizu, J Qian, Jeong Hun Kim, JH Kim, Jin Hyoung Kim, K Sun, L Sidossis, LA Kim, LE Smith, M Bagchi, M Tolentino, Marcus Fruttiger, Marià Alemany, MB Powner, Michael B. Powner, MO Stefanini, MS Gordon, P van Wijngaarden, RL Avery, RL Avery, Sung Wook Park, T Miyake, T Sato, WC Wu, Y Cao, Y Xue   +40 more
core   +6 more sources

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo

Scientific Reports, 2021
The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer.
Tetsuo Mashima, Takeru Wakatsuki, Naomi Kawata, Myung-Kyu Jang, Akiko Nagamori, Haruka Yoshida, Kenichi Nakamura, Toshiro Migita, Hiroyuki Seimiya, Kensei Yamaguchi   +9 more
doaj   +1 more source

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Frontiers in Oncology, 2021
BackgroundIn recent years, immune checkpoint inhibitors (ICIs) in combination with chemotherapy have increased survival in patients with advanced non-small cell lung cancer (NSCLC).
Keiko Tanimura, Tadaaki Yamada, Ayaka Omura, Shinsuke Shiotsu, Nobutaka Kataoka, Takayuki Takeda, Ryusuke Taniguchi, Takahiro Yamada, Mayumi Takeuchi, Yusuke Chihara, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Koichi Takayama   +14 more
doaj   +1 more source

Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea

BMC Health Services Research, 2023
Background We determined the cost-effectiveness of the anti-vascular endothelial growth factor (VEGF) intravitreal injection versus panretinal photocoagulation (PRP) for patients with proliferative diabetic retinopathy (PDR) in South Korea.
Hyeon-Jeong Lee, Songhee Cho, Jungeun Park, Yan Jin, Hyung Min Kim, Donghyun Jee   +5 more
doaj   +1 more source

Comparison of micropulse subthreshold laser plus anti-VEGF versus anti-VEGF alone in diabetic macular edema: Systematic review

Indian Journal of Ophthalmology, 2023
Intravitreal injection of anti- Vascular Endothelial Growth Factor (VEGF)is commonly used to treat patients with diabetic macular edema (DME). However, the injection alone requires high cost and compliance.
Parangeni M Lubis, Marcelius P Prabaniswara, Andi Arus Victor   +2 more
doaj   +1 more source

Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments [PDF]

International Journal of Ophthalmology
AIM: To compare the changes in preschool refractive status, ocular biological parameters, and higher-order aberrations in children with retinopathy of prematurity (ROP) after retinal laser photocoagulation or anti-vascular endothelial growth factor (anti-
Wu-Yang Jiang, Man-Hong Li, Hao Wang, Dong Niu, Yu-Sheng Wang, Zi-Feng Zhang   +5 more
doaj   +1 more source

Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion [PDF]

International Journal of Ophthalmology, 2022
AIM: To investigate the anti-inflammatory effect of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with macular edema secondary to retinal vein occlusion (RVO-ME).
Hai-Feng Qin, Fan-Jun Shi, Chao-Yang Zhang, Da-Wei Luo, Shi-Yue Qin, Jing Wu, Hai Xie, Jing-Ting Zhang, Qing-Hua Qiu, Kun Liu, Guo-Tong Xu, Guo-Xu Xu, Jing-Fa Zhang   +12 more
doaj   +1 more source

Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013–2018): a retrospective analysis of administrative data

BMJ Open, 2022
Aims The arrival of anti-vascular endothelial growth factor (anti-VEGF) therapies represented a treatment shift for several ophthalmological disorders and led to an increasing number of patients undergoing intravitreal injections.
Ana Patricia Marques, Rui Santana, António Filipe Macedo, Pedro Laires, João Victor Rocha, Marta Afonso-Silva, Ana Sofia Almeida, Julieta Fernandes, Marisa Pardal   +8 more
doaj   +1 more source